News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
Azathioprine Adds Nothing in IgA Nephropathy, Researchers Report in the Journal of the American Society of Nephrology
July 19, 2010
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Medpage -- Giving a low dose of the immunosuppressant azathioprine did not add any benefit to corticosteroid treatment for IgA nephropathy, a small randomized trial showed.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Postmarket research
MORE ON THIS TOPIC
FDA
Novo’s turnaround plan, weight loss wins, Ultragenyx’s Sanfilippo approval, IPO blitz
September 23, 2026
·
2 min read
·
Jef Akst
FDA
Compass vows to press on with FDA application despite new trial request
September 22, 2026
·
3 min read
·
Annalee Armstrong
Obesity
Viking achieves ‘maintenance trifecta’ as GLP-1/GIP dual agonist exceeds expectations
September 22, 2026
·
3 min read
·
Heather McKenzie
Clinical research
Vertex opens up larger kidney disease opportunity with mid-stage readout
September 22, 2026
·
3 min read
·
Annalee Armstrong
